pindolol has been researched along with Body Weight in 33 studies
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638)
pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty patients with mild to moderate essential hypertension, uncontrolled with diuretics alone, were evaluated in a double-blind randomized study that compared the effect of indoramin plus hydrochlorothiazide with that of pindolol plus hydrochlorothiazide." | 9.06 | A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension. ( Hartikainen, M; Luomanmäki, K, 1986) |
| "The antihypertensive effects on metoprolol and pindolol were compared in 50 patients with essential hypertension belonging to WHO stage 1 or 2." | 9.04 | A comparison between metoprolol and pindolol in the treatment of essential hypertension. ( Pohjola, M; Tuomilehto, J, 1978) |
| "This study investigated the effects of myocardial infarction (MI)-induced cardiac failure and treatment with an angiotensin-converting enzyme (ACE) inhibitor perindopril (2 mg/kg/day) on rat beta-adrenoceptor (beta-ar) subtypes in anatomically defined regions of infarcted left ventricular (LV) free wall and noninfarcted tissue from right ventricle (RV) by using autoradiography." | 7.70 | Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril. ( Gu, XH; Kompa, AR; Summers, RJ, 1998) |
| "This is the first long-term study of pindolol in a population-based sample of men with newly diagnosed hypertension." | 7.67 | Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension. ( Carlson, LA; Ribacke, M; Terént, A, 1989) |
| "Ten patients (mean age 53 years) with essential hypertension have been studied at rest and during exercise following oral treatment for 6 weeks with a new beta-adrenoceptor blocking agent, bopindolol." | 7.67 | Haemodynamic effects of short-term treatment with bopindolol in essential hypertension. ( Brandstetter, G; Fitscha, P; Meisner, W; Tiso, B, 1988) |
| "20 essential hypertension patients with diastolic blood pressure of 100-140 mm Hg were treated with increasing doses (15-45 mg/day by mouth) of pindolol for 14 weeks after an initial placebo period of 5 weeks." | 7.65 | [Blood pressure and renin activity in essential hypertension under pindolol]. ( Beckerhoff, R; Furrer, J; Nussberger, J; Schmied, U; Siegenthaler, W; Vetter, W; Würsten, D, 1976) |
| "Therefore, hypertension and cardiac hypertrophy were dissociable in this model when pindolol was administered from the onset of hypertension." | 5.28 | Reduction of cardiac hypertrophy in renal hypertensive rabbits with pindolol. ( Cimini, CM; Gonzalez, MA; Weiss, HR, 1991) |
| "Sixty patients with mild to moderate essential hypertension, uncontrolled with diuretics alone, were evaluated in a double-blind randomized study that compared the effect of indoramin plus hydrochlorothiazide with that of pindolol plus hydrochlorothiazide." | 5.06 | A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension. ( Hartikainen, M; Luomanmäki, K, 1986) |
| "The long-term efficacy of isradipine, a new dihydropyridine calcium antagonist with marked vascular selectivity, was evaluated in 17 patients with essential hypertension." | 5.06 | The long-term effect of isradipine in pindolol-treated patients. ( Andrén, L; Dahlöf, B; Eggertsen, R; Hansson, L; Jern, S; Svensson, A, 1987) |
| "Thirty patients with essential hypertension (supine diastolic blood pressure 100 to 115 mm Hg) were treated in a randomized, double-blind study with either pindolol (mean dose 28 +/- 5 mg twice a day) or methyldopa (673 +/- 158 mg three times a day) for 12 weeks after a 3-week, single-blind placebo period." | 5.05 | Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine. ( Carter, CH; Eddy, H; Winer, N, 1982) |
| "The antihypertensive effects on metoprolol and pindolol were compared in 50 patients with essential hypertension belonging to WHO stage 1 or 2." | 5.04 | A comparison between metoprolol and pindolol in the treatment of essential hypertension. ( Pohjola, M; Tuomilehto, J, 1978) |
| "This study investigated the effects of myocardial infarction (MI)-induced cardiac failure and treatment with an angiotensin-converting enzyme (ACE) inhibitor perindopril (2 mg/kg/day) on rat beta-adrenoceptor (beta-ar) subtypes in anatomically defined regions of infarcted left ventricular (LV) free wall and noninfarcted tissue from right ventricle (RV) by using autoradiography." | 3.70 | Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril. ( Gu, XH; Kompa, AR; Summers, RJ, 1998) |
| "This is the first long-term study of pindolol in a population-based sample of men with newly diagnosed hypertension." | 3.67 | Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension. ( Carlson, LA; Ribacke, M; Terént, A, 1989) |
| "Ten patients (mean age 53 years) with essential hypertension have been studied at rest and during exercise following oral treatment for 6 weeks with a new beta-adrenoceptor blocking agent, bopindolol." | 3.67 | Haemodynamic effects of short-term treatment with bopindolol in essential hypertension. ( Brandstetter, G; Fitscha, P; Meisner, W; Tiso, B, 1988) |
| "20 essential hypertension patients with diastolic blood pressure of 100-140 mm Hg were treated with increasing doses (15-45 mg/day by mouth) of pindolol for 14 weeks after an initial placebo period of 5 weeks." | 3.65 | [Blood pressure and renin activity in essential hypertension under pindolol]. ( Beckerhoff, R; Furrer, J; Nussberger, J; Schmied, U; Siegenthaler, W; Vetter, W; Würsten, D, 1976) |
| "Treatment with isradipine alone caused a sustained reduction in blood pressure (-22/-10 mm Hg, P < 0." | 1.29 | Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment. ( Berne, C; Lind, L; Lithell, H; Pollare, T, 1994) |
| "This study was designed to clarify whether chronic administration of metoprolol had any influence on cardiac beta-adrenergic receptors (BAR) in doxorubicin (DOX)-induced cardiac damage." | 1.28 | Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats. ( Fujita, N; Hiroe, M; Horie, T; Hosoda, S; Ohta, Y, 1991) |
| "Therefore, hypertension and cardiac hypertrophy were dissociable in this model when pindolol was administered from the onset of hypertension." | 1.28 | Reduction of cardiac hypertrophy in renal hypertensive rabbits with pindolol. ( Cimini, CM; Gonzalez, MA; Weiss, HR, 1991) |
| "The pindolol-treated and propranolol-treated rats gained weight during the cold-acclimatization period." | 1.28 | Influence of two beta-adrenoceptor antagonists, propranolol and pindolol, on cold adaptation in the rat. ( Huttunen, P; Kortelainen, ML; Lapinlampi, T, 1990) |
| "Pindolol was administered with the food during the entire pregnancy period." | 1.27 | Hemodynamic changes after chronic pindolol administration in pregnant renal hypertensive rats. ( Karlsson, K; Ljungblad, U; Lundgren, Y, 1983) |
| "Bopindolol is a new beta blocker with a long duration of action and antihypertensive properties at low dosage." | 1.27 | Antihypertensive treatment with bopindolol alone or combined with a diuretic in general practice. ( Bousquet, JC; Weidmann, P, 1986) |
| "The body weight was reduced by 41% and the heart weight by 38% in these starving periods." | 1.27 | Beta-adrenergic receptor in heart of starved rats. ( Akikawa, K; Kubo, M; Matsubara, M; Nakagawa, K, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 18 (54.55) | 18.7374 |
| 1990's | 14 (42.42) | 18.2507 |
| 2000's | 1 (3.03) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yalcin, I | 1 |
| Aksu, F | 1 |
| Belzung, C | 1 |
| Williams, RS | 1 |
| Caron, MG | 1 |
| Daniel, K | 1 |
| Tsujimoto, G | 1 |
| Manger, WM | 1 |
| Hoffman, BB | 1 |
| Maebashi, M | 1 |
| Yoshinaga, K | 1 |
| Suzuki, M | 1 |
| Van Brummelen, P | 1 |
| Bolli, P | 1 |
| Koolen, MI | 1 |
| Staehelin, HB | 1 |
| Bühler, FR | 1 |
| Lundgren, Y | 1 |
| Ljungblad, U | 1 |
| Karlsson, K | 1 |
| Winer, N | 1 |
| Carter, CH | 1 |
| Eddy, H | 1 |
| Moser, M | 1 |
| Lunn, J | 1 |
| Tejani-Butt, SM | 2 |
| Paré, WP | 1 |
| Yang, J | 2 |
| Lind, L | 1 |
| Berne, C | 1 |
| Pollare, T | 1 |
| Lithell, H | 1 |
| Bazan, A | 1 |
| Van de Velde, E | 1 |
| Fraeyman, N | 1 |
| Kim, Y | 1 |
| Flügge, G | 1 |
| Ahrens, O | 1 |
| Fuchs, E | 1 |
| Chang, HR | 1 |
| Chen, SS | 1 |
| Tsao, DA | 1 |
| Cheng, JT | 1 |
| Ho, CK | 1 |
| Yu, HS | 1 |
| Mersmann, HJ | 1 |
| Carey, GB | 1 |
| Smith, EO | 1 |
| Gu, XH | 1 |
| Kompa, AR | 1 |
| Summers, RJ | 1 |
| Tuomilehto, J | 1 |
| Pohjola, M | 1 |
| Nussberger, J | 1 |
| Vetter, W | 1 |
| Furrer, J | 1 |
| Beckerhoff, R | 1 |
| Würsten, D | 1 |
| Schmied, U | 1 |
| Siegenthaler, W | 1 |
| Brecht, HM | 1 |
| Werner, E | 1 |
| Schoeppe, W | 1 |
| Kudlacz, EM | 1 |
| Spencer, JR | 1 |
| Slotkin, TA | 2 |
| Pracyk, JB | 1 |
| Fujita, N | 1 |
| Hiroe, M | 1 |
| Ohta, Y | 1 |
| Horie, T | 1 |
| Hosoda, S | 1 |
| Cimini, CM | 1 |
| Gonzalez, MA | 1 |
| Weiss, HR | 1 |
| Kortelainen, ML | 1 |
| Huttunen, P | 1 |
| Lapinlampi, T | 1 |
| Luomanmäki, K | 1 |
| Hartikainen, M | 1 |
| Weidmann, P | 1 |
| Bousquet, JC | 1 |
| Terént, A | 1 |
| Ribacke, M | 1 |
| Carlson, LA | 1 |
| Nakagawa, K | 1 |
| Matsubara, M | 1 |
| Akikawa, K | 1 |
| Kubo, M | 1 |
| Fitscha, P | 1 |
| Meisner, W | 1 |
| Brandstetter, G | 1 |
| Tiso, B | 1 |
| Dahlöf, B | 1 |
| Andrén, L | 1 |
| Eggertsen, R | 1 |
| Jern, S | 1 |
| Svensson, A | 1 |
| Hansson, L | 1 |
| Lehtonen, A | 1 |
| Waal-Manning, HJ | 1 |
| Simpson, FO | 1 |
8 trials available for pindolol and Body Weight
| Article | Year |
|---|---|
Plasma lipid fractions during long-term monotherapy with the ISA-containing beta-adrenoceptor blocker bopindolol in hypertensive patients.
Topics: Adult; Blood Pressure; Body Weight; Cholesterol; Female; Heart Rate; Humans; Hypertension; Male; Mid | 1984 |
Effects of pindolol and methyldopa on blood pressure and plasma norepinephrine.
Topics: Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperten | 1982 |
Comparative effects of pindolol and hydrochlorothiazide in black hypertensive patients.
Topics: Black People; Blood Glucose; Blood Pressure; Body Weight; Humans; Hydrochlorothiazide; Hypertension; | 1981 |
A comparison between metoprolol and pindolol in the treatment of essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Body Weight; Drug Evaluation; Female; Heart Rate; Humans; Hypert | 1978 |
A double-blind comparison of indoramin and pindolol added to hydrochlorothiazide for the treatment of mild to moderate hypertension.
Topics: Adult; Aged; Blood Pressure; Body Weight; Clinical Trials as Topic; Double-Blind Method; Drug Therap | 1986 |
The long-term effect of isradipine in pindolol-treated patients.
Topics: Aged; Body Weight; Calcium Channel Blockers; Double-Blind Method; Drug Therapy, Combination; Edema; | 1987 |
Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.
Topics: Adult; Atenolol; Blood Glucose; Body Weight; Cholesterol, LDL; Cholesterol, VLDL; Drug Administratio | 1988 |
Pindolol: a comparison with other antihypertensive drugs and a double-blind placebo trial.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Body Weight; Clinical Trials as Topic; Drug In | 1974 |
25 other studies available for pindolol and Body Weight
| Article | Year |
|---|---|
Effects of desipramine and tramadol in a chronic mild stress model in mice are altered by yohimbine but not by pindolol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics, Opioid; Animals; Antidepressi | 2005 |
Skeletal muscle beta-adrenergic receptors: variations due to fiber type and training.
Topics: Adenylyl Cyclases; Animals; Body Weight; Heart Rate; Iodocyanopindolol; Male; Muscles; Oxygen Consum | 1984 |
Desensitization of beta-adrenergic receptors by pheochromocytoma.
Topics: Adipose Tissue; Adrenal Gland Neoplasms; Animals; Body Weight; Cell Membrane; Cyclic AMP; Energy Int | 1984 |
Effect of pindolol, a beta-adrenoceptor blocking agent, on lipid metabolism.
Topics: Adipose Tissue; Animals; Body Weight; Carnitine; Lipid Metabolism; Lipoprotein Lipase; Lipoproteins; | 1984 |
Hemodynamic changes after chronic pindolol administration in pregnant renal hypertensive rats.
Topics: Animals; Blood Pressure; Body Weight; Cardiac Output; Female; Hemodynamics; Hypertension, Renal; Mat | 1983 |
Effect of repeated novel stressors on depressive behavior and brain norepinephrine receptor system in Sprague-Dawley and Wistar Kyoto (WKY) rats.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Body Weight; Brain; Carrier Prot | 1994 |
Metabolic effects of isradipine as monotherapy or in combination with pindolol during long-term antihypertensive treatment.
Topics: Adult; Blood Glucose; Blood Pressure; Body Weight; Drug Therapy, Combination; Female; Hemoglobin A; | 1994 |
Effect of age on beta-receptors, Gs alpha- and Gi alpha- proteins in rat heart.
Topics: Adenylyl Cyclases; Aging; Amino Acid Sequence; Animals; Body Weight; GTP-Binding Proteins; Heart Ven | 1994 |
A time course of altered thyroid states on the noradrenergic system in rat brain by quantitative autoradiography.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 R | 1994 |
Interaction between beta blockers and epinephrine on hemodynamics of spontaneously hypertensive rats.
Topics: Acebutolol; Adult; Animals; Body Weight; Drug Interactions; Epinephrine; Female; Hemodynamics; Human | 1993 |
Beta-adrenoceptors in the tree shrew brain. II. Time-dependent effects of chronic psychosocial stress on [125I]iodocyanopindolol bindings sites.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Anta | 1997 |
Change of cardiac beta-adrenoceptors in lead-exposed rats.
Topics: Animals; Body Weight; Iodocyanopindolol; Lead; Myocardium; Organ Size; Organometallic Compounds; Pin | 1997 |
Adipose tissue beta-adrenergic and A1 adenosine receptors in suckling pigs.
Topics: Adipocytes; Adipose Tissue; Aging; Animals; Animals, Suckling; Body Weight; Female; Iodocyanopindolo | 1997 |
Regulation of beta-adrenoceptors in a rat model of cardiac failure: effect of perindopril.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Autoradiography; Blood Pressure; Body Weight; Dow | 1998 |
[Blood pressure and renin activity in essential hypertension under pindolol].
Topics: Adolescent; Adult; Blood Pressure; Body Weight; Female; Heart Rate; Humans; Hypertension; Male; Midd | 1976 |
Increase of total body potassium and decrease of exchangeable sodium after long-term treatment with a beta-receptor-blocking agent (prindolol) in essential hypertension.
Topics: Adult; Body Weight; Female; Humans; Hypertension; Male; Middle Aged; Pindolol; Potassium; Renin; Sod | 1976 |
Postnatal alterations in beta-adrenergic receptor binding in rat brain regions after continuous prenatal exposure to propranolol via maternal infusion.
Topics: Animals; Body Weight; Brain; Brain Stem; Cerebellum; Female; Infusions, Intravenous; Maternal-Fetal | 1991 |
Thyroid hormone differentially regulates development of beta-adrenergic receptors, adenylate cyclase and ornithine decarboxylase in rat heart and kidney.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenylyl Cyclases; Animals; Animals, Newborn; Body Weight; B | 1991 |
Chronic effects of metoprolol on myocardial beta-adrenergic receptors in doxorubicin-induced cardiac damage in rats.
Topics: Animals; Body Weight; Doxorubicin; Heart Diseases; Hemodynamics; In Vitro Techniques; Iodocyanopindo | 1991 |
Reduction of cardiac hypertrophy in renal hypertensive rabbits with pindolol.
Topics: Animals; Body Weight; Cardiomegaly; Coronary Circulation; Hemodynamics; Hypertension, Renal; Nephrec | 1991 |
Influence of two beta-adrenoceptor antagonists, propranolol and pindolol, on cold adaptation in the rat.
Topics: Adaptation, Physiological; Adipose Tissue, Brown; Adrenergic beta-Antagonists; Animals; Body Tempera | 1990 |
Antihypertensive treatment with bopindolol alone or combined with a diuretic in general practice.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Body Weight; Diuretics; Female; Heart Rate | 1986 |
Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension.
Topics: Adult; Aged; Body Weight; Cholesterol; Cholesterol, LDL; Humans; Hypertension; Lipids; Lipoproteins; | 1989 |
Beta-adrenergic receptor in heart of starved rats.
Topics: Animals; Anorexia Nervosa; Body Weight; Female; Iodocyanopindolol; Myocardium; Pindolol; Pituitary G | 1987 |
Haemodynamic effects of short-term treatment with bopindolol in essential hypertension.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Body Weight; Exercise Test; Female; Heart Rate; | 1988 |